Can I Take Alpha-Lipoic Acid with Praluent (Alirocumab)?

How Alirocumab Works and Why Supplement Interactions Are Rare

Alirocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9 from degrading LDL receptors on the hepatocyte surface [1]. More LDL receptors remain available to clear circulating LDL-C from the bloodstream. That mechanism sits entirely outside the cytochrome P450 system.

Monoclonal Antibody Clearance Is Distinct from Small-Molecule Drug Metabolism

Small-molecule drugs like statins pass through CYP3A4, CYP2C9, or other hepatic enzymes, creating opportunities for supplements to speed up or slow down their breakdown. Alirocumab does not. It is degraded through proteolytic catabolism, the same pathway the body uses to recycle endogenous immunoglobulins [2]. This means compounds that induce or inhibit liver enzymes have no measurable effect on alirocumab serum concentrations.

What the ODYSSEY Trials Tell Us About Co-Administration

In the ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 61% at 24 weeks when added to maximally tolerated statin therapy [3]. Patients in ODYSSEY trials used a range of concomitant medications, and the prescribing information lists no clinically significant drug-drug interactions [2]. No supplement-specific interaction studies exist for alirocumab, but the proteolytic clearance pathway makes pharmacokinetic interference biologically implausible.

What Alpha-Lipoic Acid Does in the Body

Alpha-lipoic acid is an organosulfur compound that functions as a cofactor for mitochondrial enzyme complexes, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase [4]. It is both water- and fat-soluble, giving it antioxidant activity in multiple cellular compartments. Supplemental doses typically range from 300 to 1,800 mg per day.

Glucose-Lowering Properties

ALA enhances insulin-stimulated glucose disposal. A meta-analysis of 20 randomized controlled trials (N=1,245) found that ALA supplementation reduced fasting blood glucose by a weighted mean of 10.13 mg/dL (95% CI: 4.48 to 15.79) and HbA1c by 0.35% compared to placebo [5]. The NATHAN 1 trial, a four-year RCT of 460 patients with diabetic polyneuropathy, used 600 mg/day of ALA and confirmed its tolerability profile alongside standard diabetes therapy [6].

Thyroid Hormone Modulation

ALA may inhibit the peripheral conversion of thyroxine (T4) to triiodothyronine (T3) by reducing deiodinase enzyme activity [7]. A small clinical study (N=32) of patients receiving levothyroxine found that 600 mg/day of ALA for two weeks lowered free T3 levels while TSH rose modestly, suggesting reduced T4-to-T3 conversion [7]. This effect is pharmacodynamic, not pharmacokinetic. It does not change how alirocumab behaves.

Lipid Effects of ALA

Some evidence suggests ALA has a modest lipid-lowering effect of its own. A 2018 systematic review and meta-analysis of 12 RCTs (N=522) reported that ALA supplementation reduced total cholesterol by 8.8 mg/dL and LDL-C by 7.8 mg/dL, though results varied by dose and population [8]. These reductions are clinically small compared to the 50 to 60% LDL-C reduction produced by alirocumab. The lipid effects of ALA are additive, not antagonistic.

Interaction Analysis: Pharmacokinetic vs. Pharmacodynamic

The distinction between pharmacokinetic (PK) and pharmacodynamic (PD) interactions matters here. A PK interaction changes how much of a drug reaches the bloodstream or how fast it is eliminated. A PD interaction changes what the drug does once it is there.

No Pharmacokinetic Interaction

Alirocumab is not metabolized by CYP enzymes, is not a substrate for P-glycoprotein efflux transporters, and is not protein-bound in the way small molecules are [2]. ALA's known enzyme effects (mild CYP2C9 inhibition observed in vitro) have no pathway through which to alter alirocumab levels [9]. There is no PK interaction.

Pharmacodynamic Considerations Are Indirect

Two PD effects deserve attention, though neither involves alirocumab directly.

First, ALA's glucose-lowering action. If a patient on alirocumab also takes metformin, a sulfonylurea, or insulin for type 2 diabetes, adding ALA could push blood glucose lower than expected. The 2023 American Diabetes Association Standards of Care recommend individualized glycemic targets and warn that stacking glucose-lowering agents without monitoring increases hypoglycemia risk [10].

Second, ALA's effect on thyroid hormone conversion. Patients with hypothyroidism who take levothyroxine alongside alirocumab should know that ALA may blunt the downstream availability of active T3. The American Thyroid Association guidelines note that supplements affecting thyroid hormone metabolism should be documented during dose titration [11]. This is relevant because hypothyroidism itself raises LDL-C, and undertreated thyroid disease can blunt the lipid-lowering response to any therapy, including PCSK9 inhibitors.

Blood Sugar Monitoring When Taking Both

Alirocumab itself is not associated with hypoglycemia in lipid-lowering trials. In ODYSSEY OUTCOMES (N=18,924), the rate of new-onset diabetes was 9.6% with alirocumab versus 10.1% with placebo over a median follow-up of 2.8 years, a non-significant difference [12]. The concern arises only when ALA is layered on top of existing diabetes medications.

Who Needs Closer Glucose Surveillance

Patients taking insulin, sulfonylureas, or meglitinides alongside alirocumab should check fasting glucose and postprandial glucose more frequently during the first 4 to 8 weeks after starting ALA. A reasonable target is twice-weekly fasting checks. If fasting glucose drops below 70 mg/dL on two or more readings, the diabetes medication dose (not the ALA dose) should be re-evaluated first [10].

Patients Without Diabetes

For patients who do not have diabetes and are taking alirocumab for familial hypercholesterolemia or ASCVD risk reduction, ALA's glucose effect is unlikely to cause clinical hypoglycemia. Healthy fasting glucose is typically 70 to 99 mg/dL, and the 10 to 22 mg/dL reduction seen with ALA in insulin-resistant populations does not extrapolate directly to normoglycemic individuals [5].

Thyroid Monitoring Considerations

Hypothyroidism is a secondary cause of hyperlipidemia. The 2014 National Lipid Association recommendations state that clinicians should rule out or treat hypothyroidism before attributing elevated LDL-C entirely to genetic or dietary causes [13]. Dr. Anne Cappola, a professor of medicine at the University of Pennsylvania and former president of the American Thyroid Association, has noted: "Unrecognized thyroid dysfunction can confound the response to lipid-lowering therapy. Checking TSH before and during treatment is standard practice" [11].

Practical Thyroid Lab Schedule

If you take levothyroxine, alirocumab, and ALA concurrently, check TSH and free T3 at baseline, then again at 6 and 12 weeks after adding ALA. If free T3 drops or TSH rises above your target range, your prescriber may need to adjust the levothyroxine dose upward by 12.5 to 25 mcg. Some clinicians recommend separating ALA from levothyroxine by at least 2 hours to minimize direct absorption interference, though the T4-to-T3 conversion effect is systemic and not dependent on co-ingestion timing [7].

Patients Without Thyroid Disease

If your thyroid function is normal and you are not on thyroid medication, ALA's effect on T4-to-T3 conversion is unlikely to produce clinical symptoms. A single TSH check at 12 weeks after starting ALA provides reasonable reassurance.

What to Do If You Are Already Taking Both

Many patients discover interaction questions after they have been co-administering a supplement and a prescription drug for weeks or months. That is fine. If you have been taking ALA and Praluent together without symptoms, the combination is likely well tolerated for you.

Step-by-Step Assessment

Check your most recent lipid panel. If LDL-C is at or below your target (typically <70 mg/dL for ASCVD patients per 2018 AHA/ACC guidelines), alirocumab efficacy is not compromised [14]. Review your most recent fasting glucose or HbA1c. If these values are stable and within your goal range, ALA is not causing problematic glucose shifts.

When to Talk to Your Prescriber

Contact your prescriber if you notice any of the following after adding ALA: episodes of lightheadedness or shakiness between meals (possible hypoglycemia), new fatigue or cold intolerance (possible reduced T3), or an unexplained rise in LDL-C on repeat testing (possible undertreated thyroid disease).

Dr. Robert Eckel, a professor of medicine at the University of Colorado and past president of the American Heart Association, has stated regarding supplement use with lipid-lowering therapies: "Patients should inform their cardiologist of every supplement they take. Interactions may not always be direct, but the downstream metabolic effects can alter the clinical picture" [14].

Dose-Separation Windows and Practical Timing

Because alirocumab is injected subcutaneously every 2 weeks (75 mg or 150 mg) or every 4 weeks (300 mg), it does not interact with oral supplements in the GI tract at all [2]. There is no absorption competition. You can take ALA at any time relative to your Praluent injection without concern.

Timing ALA Around Other Medications

The more relevant timing question involves other oral medications in your regimen. ALA should be taken on an empty stomach for best absorption (30 minutes before a meal). If you also take levothyroxine (best absorbed on an empty stomach, 30 to 60 minutes before food), separate the two by at least 2 hours. If you take a statin, no specific separation from ALA is required.

Suggested Daily Schedule

A workable timing pattern for a patient on levothyroxine, alirocumab, a statin, and ALA: levothyroxine upon waking, ALA 2 hours later (30 minutes before lunch), statin in the evening. Praluent injection on its scheduled day at any convenient time [2].

Safety Signals and Contraindications

ALA is classified as Generally Recognized as Safe (GRAS) at doses up to 600 mg/day in most regulatory frameworks [4]. Common side effects include mild GI discomfort (nausea, abdominal fullness) in roughly 10 to 15% of users at doses above 600 mg [6].

Who Should Avoid ALA

Patients with a history of insulin autoimmune syndrome (Hirata disease) should not take ALA. Case reports, primarily from Japan, have linked ALA supplementation to severe hypoglycemia mediated by anti-insulin antibodies, particularly in individuals carrying the HLA-DRB1*0406 allele [15]. This is rare but serious. If you have unexplained hypoglycemia after starting ALA, insulin antibody testing is warranted.

Alirocumab-Specific Precautions

Alirocumab's main adverse effects are injection-site reactions (7.2% vs. 5.1% placebo in ODYSSEY LONG TERM) and, uncommonly, neurocognitive events that were not confirmed as causal in the EBBINGHAUS substudy (N=2,200) [3][16]. Neither of these is worsened by ALA.

Summary of Monitoring Recommendations

Before adding ALA to a Praluent regimen, obtain a baseline lipid panel, fasting glucose (or HbA1c), TSH, and free T3. Repeat these labs at 12 weeks. If all values remain stable, continue annual monitoring. Adjust levothyroxine if TSH rises. Adjust diabetes medications (not ALA) if glucose drops too low. No alirocumab dose changes are expected based on ALA co-administration.